Multivariate HRs of hepatocellular carcinoma according to disease phase
| HBV seromarkers at baseline or follow-up | No. (%) of participants (N=2946) | No. of HCC cases | Person-years of follow-up | Incidence rate per 100 000 person-years | Crude HR (95% CI) | p Value | Multivariate adjusted HR (95% CI)* | p Value |
|---|---|---|---|---|---|---|---|---|
| HBV DNA undetectable at baseline or follow-up/HBsAg clearance | 516 (18) | 8 | 8537.7 | 93.70 | 1.0 | 1.0 | ||
| HBV DNA undetectable at baseline or follow-up/no HBsAg clearance | 635 (22) | 11 | 10 353.9 | 106.24 | 1.25 (0.50 to 3.11) | 0.63 | 1.53 (0.60 to 3.90) | 0.37 |
| Baseline HBeAg (–) with persistently detectable HBV DNA during follow-up | 1351 (46) | 65 | 21 849.4 | 297.49 | 3.52 (1.69 to 7.34) | <0.001 | 3.99 (1.78 to 8.99) | <0.001 |
| Baseline HBeAg (+) with HBeAg clearance during follow-up/persistently detectable HBV DNA | 151 (5) | 22 | 2434.0 | 903.87 | 10.77 (4.79 to 24.19) | <0.001 | 15.13 (5.95 to 38.51) | <0.001 |
| Persistently HBeAg (+) | 252 (9) | 47 | 3833.9 | 1225.91 | 14.83 (7.01 to 31.38) | <0.001 | 20.39 (8.56 to 48.57) | <0.001 |
*Adjusted for age, sex, cigarette smoking, alcohol consumption, history of diabetes, ALT level and serum HBsAg level.